Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Lifted by Monument Capital Management

Monument Capital Management increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 853 shares of the medical research company’s stock after buying an additional 50 shares during the quarter. Monument Capital Management’s holdings in Thermo Fisher Scientific were worth $453,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Sugarloaf Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton increased its stake in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after buying an additional 19 shares during the period. Tsfg LLC increased its stake in shares of Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the period. Pacifica Partners Inc. increased its stake in shares of Thermo Fisher Scientific by 16.5% in the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after buying an additional 20 shares during the period. Finally, Retirement Planning Group LLC increased its stake in shares of Thermo Fisher Scientific by 4.9% in the 4th quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock valued at $237,000 after buying an additional 21 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $548.37 on Tuesday. The firm has a market cap of $209.32 billion, a price-to-earnings ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. The stock’s 50-day moving average is $571.30 and its 200-day moving average is $528.18. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the company posted $5.40 earnings per share. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMO. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.